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Abstract  
 
Sorafenib (Nexavar) is a multikinase inhibitor which has demonstrated both anti-proliferative and anti-
angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumor cell [c-RAF 
(proto-oncogene serine/threonine-protein kinase), BRAF, V600EBRAF, c-KIT, and FMS-like tyrosine kinase 
3] and in the tumor vessels (c-RAF, vascular endothelial growth factor receptor-2, vascular endothelial 
growth factor receptor-3, and platelet-derived growth factor receptor β). Since several years, Sorafenib has 
been approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma. After 
previous studies showing that Sorafenib was able to inhibit oncogenic RET mutants, V600EBRAF, and 
angiogenesis and growth of orthotopic anaplastic thyroid cancer xenografts in nude mice, some clinical 
trials proved the effectiveness of Sorafenib in advanced thyroid cancer. Currently, the evaluation of the 
clinical safety and efficacy for the treatment of advanced thyroid cancer is ongoing. This paper reviews the 
antineoplastic effect of Sorafenib in thyroid cancer. 
Several studies have evaluated (or are ongoing) the long term efficacy and tolerability of Sorafenib in 
patients with papillary and medullary aggressive thyroid cancer. The results suggest Sorafenib is a 
promising therapeutic option in patients with advanced thyroid cancer not responsive to traditional 
therapeutic strategies. 
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1. Introduction 
Thyroid cancer is the most prevalent type of endocrine malignancy and it represents the 7th most common 
cause of any new malignancy in the US for women, (25480 cases in 2007, 3.8% of new cases), while 
causing only about 1% of new cases in men (8070 cases in 2007; incidence rank: 14th) [1]. 
While in the last fourty years the incidence of thyroid cancer has been increasing, the percentage of cancer 
deaths per year, relative to the number of new cases, has decreased from 15% to 5% [1]. 
Differentiated thyroid cancer (DTC) is the most common histological subtype and it is primarily responsible 
for the increased overall incidence of thyroid cancer [2]. After surgery, patients with papillary (PTC) and 
follicular (FTC) thyroid cancer are followed by basal and thyroid-stimulating hormone (TSH)-stimulated 
thyroglobulin (Tg) determination, and by neck ultrasonography [3-6].  
However, the improvement of survival leads to an increased cancer related morbidity and to a higher 
number of advanced diseases that are less responsive to the traditional therapeutic modalities (i.e., 
combination of surgery radioiodine ablation and TSH suppressive therapy). Cellular dedifferentiation 
occurs in up to 5% of cases during tumor progression and it is characterized by more aggressive growth, 
metastatic spread and loss of iodide uptake ability. Also radiotherapy and conventional chemotherapy are of 
modest importance in the treatment of dedifferentiated thyroid cancer [7]. The only systemic therapy 
approved in most countries is doxorubicin, which has traditionally been a limited option because complete 
or partial responses (PR) are rare and toxicity profile is unfavourable. Therefore, the management of 
dedifferentiated thyroid cancer requires new therapeutic options.  
Some molecular pathways are involved in the development of thyroid cancer. In PTC, rearranged during 
transfection/PTC (RET/PTC) rearrangements are found in 30-40%, RAS mutations in about 10%, and 
BRAF mutations in approximately 40-50%, with no overlap among these mutations, whereas a higher 
prevalence of BRAF mutations (up to 70%) has been observed in dedifferentiated papillary thyroid cancer 
(DePTC) [8,9]. 
In FTC, RAS mutations are found in 40-50% of tumors [10] and may also correlate with tumor 
dedifferentiation and less favorable prognosis [11]. 
PAX8-peroxisome proliferator-activated receptor (PPAR)γ rearrangement (PAX8-PPARγ) occurs in  ~ 35% 
of conventional follicular carcinomas, and with lower prevalence in oncocytic (Hurthle cell) carcinomas 
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[12]. Tumors harboring PAX8-PPARγ tend to present at a younger age, be smaller in size, and more 
frequently have vascular invasion. 
Alteration of the RET proto-oncogene plays a casual role in the familial forms of medullary thyroid 
carcinoma (MTC) and has also been found in sporadic forms of the disease. 
The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible 
the development of new therapeutic drugs able to block oncogenic kinases (V600EBRAF, RET/PTC) or 
signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor 
receptors] involved in cellular growth and proliferation [13].  
 
2. RET 
The RET gene is located on chromosome 10q11.2 and it encodes a transmembrane receptor [14].   
The natural alternative splicing of the RET gene results in the production of 3 different isoforms of the 
protein RET. RET51, RET43 and RET9 contain 51, 43 and 9 amino acids in their C-terminal tail 
respectively. The biological roles of isoforms RET51 and RET9 are the most well studied in vivo as these 
are the most common isoforms in which RET occurs [15]. 
RET is the receptor for members of the glial cell line-derived neurotrophic factor family of extracellular 
signalling molecules or ligands [15].  
RET activation triggers autophosphorylation of tyrosine residues that serve as docking sites for adaptor 
proteins, which coordinate cellular signal transduction pathways [eg, mitogen-activated protein kinase 
(MAPK), phosphatidylinositol 3-kinase, etc.] which are important in the regulation of cell growth [15].  
 
3. PTC 
In PTC, RET can be activated by chromosomal rearrangement known as RET/PTC rearrangement [15]. In 
RET/PTC, the 3' portion of the RET gene is fused to the 5' portion of various unrelated genes. At least 13 
types of RET/PTC have been reported to date, all formed by the fusion of RET to different partners [15]. 
The two most common rearrangement types, RET/PTC1 and RET/PTC3, account for the vast majority of 
all rearrangements found in PTCs. RET/PTC is tumorigenic in thyroid follicular cells, as it transforms 
thyroid cells in culture and gives rise to thyroid cancers in transgenic mice [15]. 
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Papillary carcinomas with RET/PTC rearrangements typically present at younger age and have a high rate 
of lymph node metastases, classic papillary histology and possibly more favorable prognosis, particularly 
those harboring RET/PTC1 [16].  
In tumors arising after radiation exposure, RET/PTC1 was found to be associated with classic papillary 
histology, whereas RET/PTC3 type was more common in the solid variants [17].  
BRAF mutations are highly prevalent in PTCs with classical histology and in the tall cell variant [18]. In 
many studies, the presence of BRAF mutation has been found to correlate with aggressive tumor 
characteristics such as extrathyroidal extension, advanced tumor stage at presentation, and lymph node or 
distant metastases [19]. BRAF mutations have also been associated with the decreased ability of tumors to 
trap radioiodine and treatment failure of the recurrent disease, which may be due to the dysregulation of 
function of the sodium iodide symporter [19].  
In PTCs, RAS mutations occur in ~10% of tumors. PTCs with RAS mutations almost always have the 
follicular variant histology [16]. Some studies have reported the association between RAS mutations and 
more aggressive behaviour of PTC and with higher frequency of distant metastases [20].  
 
4. MTC 
MTC originates from the calcitonin-producing neuroendocrine cells of the thyroid gland and accounts for 
5% of all thyroid malignancies [21]. MTC is usually a slow-growing tumor, and patients with metastatic 
disease have 10-year overall survival (OS) rates of 40-50% [22]. Most cases of MTC are sporadic and 
present with metastatic disease at diagnosis; approximately 20% of MTC cases occur as a component of 
multiple endocrine neoplasia syndrome type 2 (MEN2). Surgery remains the only curative modality 
available [23]. However, there are no effective therapeutic options available for distant metastatic disease 
because the tumor does not respond to external radiotherapy, radionuclide therapy or chemotherapy.  
Activating point mutations in RET can give rise to the hereditary cancer syndrome known as MEN2 [24]. 
There are three subtypes based on clinical presentation: MEN2A, MEN2B, and familial medullary thyroid 
carcinoma [25]. There is a high degree of correlation between the position of the point mutation and the 
phenotype of the disease.  
Activating mutations of the tyrosine kinase receptor RET have been reported in nearly all hereditary cases 
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of MTC and in 30-50% of sporadic tumor cases [25]. Thus, RET has become an important therapeutic 
target for MTC.  
 
5. Tyrosine Kinase Receptor Inhibitors  
Tyrosine kinase inhibitors (TKIs) are small organic compounds that affect tyrosine kinase-dependent 
oncogenic pathways, competing with the ATP-binding site of the catalytic domain of the tyrosine kinase 
[26]. Occupation of this site inhibits autophosphorylation and activation of the tyrosine kinase and prevents 
further activation of intracellular signalling pathways. TKIs can be specific to one or several homologous 
tyrosine kinases. Thus, a single TKI may target multiple tyrosine kinases [27]. Several small-molecule 
TKIs directed toward RET kinase have been tested in vitro, and in pre-clinical, and clinical studies (Table 
1 [28-40] and Table 2 [41-51]). ZD6474, also known as Vandetanib, an orally active low-molecular-weight 
receptor TKI, is a potent inhibitor of the VEGFR-2 and effectively blocks RET tyrosine kinase [41]. 
ZD6474 has been shown to block phosphorylation and signaling from RET/PTC3 and RET carrying the 
most common MEN2A and MEN2B mutations in vitro, to induce growth arrest of human papillary cancer 
cell lines carrying RET/PTC1, and to prevent tumor growth in nude mice after injection of RET/PTC3-
transformed fibroblasts or RET mutation-positive medullary cancer [52].  
Various classes of small TKIs have shown inhibition of RET activity in pre-clinical studies, including 
pyrazolopyrimidine inhibitors PP1 and PP2, 2-indolinone derivative RPI-1, and indolocarbazole derivatives 
CEP-701 and -751 [42-44]. PP1 and PP2 have been tested in pre-clinical studies and found to be effective 
in therapeutic concentrations in blocking RET/PTC signaling in vivo and abolishing its tumorigenic effects 
in experimental animals. A multikinase inhibitor SU12248 (Sunitinib) has been shown to effectively inhibit 
signaling from RET/PTC kinase in the experimental models and has been progressed to phase II clinical 
trial in radioiodine-refractory, unresectable DTC and MTC [53].  
In a recent study [54] it has been compared the effect of four TKIs (Axitinib, Sunitinib, Vandetanib, and 
XL184) on cell proliferation, RET expression and autophosphorylation, and ERK activation in cell lines 
expressing a MEN2A (MTC-TT), a MEN2B (MZ-CRC-1) mutation, and a RET/PTC (TPC-1) 
rearrangement. XL184 and Vandetanib most effectively inhibited cell proliferation and RET 
autophosphorylation. XL184 being the most potent inhibitor in MEN2A and PTC and Vandetanib the most 
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effective in MEN2B in vitro.  
A phase I dose-escalation study of oral Cabozantinib was conducted in patients with advanced solid tumors 
[55]. Eighty-five patients were enrolled, including 37 with MTC. Eighteen patients experienced tumor 
shrinkage of 30% or more, including 17 (49%) of 35 patients with MTC with measurable disease. 
Additionally, 15 (41%) of 37 patients with MTC had stable disease (SD) for at least 6 months, resulting in 
SD for 6 months or longer or confirmed PR in 68% of patients with MTC. These results suggest that 
Cabozantinib has an acceptable safety profile and is active in MTC.  
 
6. Sorafenib 
Sorafenib is a small molecular (a bi-aryl urea), multi-targeted TKI, approved for the treatment of primary 
kidney cancer [advanced renal cell carcinoma (RCC)] and advanced primary liver cancer [hepatocellular 
carcinoma (HCC)].  
It demonstrated inhibitor activity against VEGFR-2 and 3, c-Kit, platelet-derived growth factor receptors, 
RET/PTC, and Raf kinases (more avidly C-Raf than B-Raf) [56,57], and it is the only TKI able to target the 
Raf/Mek/Erk pathway (MAPK pathway). In addition, Sorafenib has been also shown to induce apoptosis 
through down-regulation of Mcl-1 in many cancer types [58]. 
Recently, Matsuse et al. [59] tested the efficacy of Sorafenib in a novel complex BRAF mutation (BRAF 
p.V600delinsYM) identified in 4/492 Japanese PTC cases (0.81%). In vitro kinase assay and western 
blotting revealed that this mutation conferred high kinase activity on the BRAF protein, leading to 
constitutive activation of the MAPK signaling pathway. The degree of all the functional characteristics was 
comparable to that of  V600EBRAF, and treatment with a BRAF inhibitor Sorafenib was also equally 
effective in this mutant [59].  
Sorafenib was approved by the U.S. Food and Drug Administration in December 2005 [60], and received 
European Commission marketing authorization in July 2006 [61], for the treatment of advanced renal 
cancer.  
In October 2007, the European Commission granted marketing authorization to the drug for the treatment of 
patients with HCC. U.S. Food and Drug Administration approval for this indication followed in November 
2007 [62]. 
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7. Pharmacokinetic (PK) Profile 
7.1 Absorption and distribution 
After administration of Nexavar tablets, the mean relative bioavailability is 38–49% when compared to an 
oral solution. The absolute bioavailability is not known. Following oral administration Sorafenib reaches 
peak plasma concentrations in approximately 3 hours. When given with a high-fat meal Sorafenib 
absorption was reduced by 30% compared to administration in the fasted state. Mean C-max and area under 
curve increased less than proportionally beyond doses of 400 mg administered twice daily. In vitro binding 
of Sorafenib to human plasma proteins is 99.5%. 
Multiple dosing of Nexavar for 7 days resulted in a 2.5- to 7-fold accumulation compared to single dose 
administration. Steady state plasma Sorafenib concentrations are achieved within 7 days, with a peak to 
trough ratio of mean concentrations of less than 2. 
 
7.2 Biotransformation and elimination 
The elimination half-life of Sorafenib is approximately 25–48 hours. Sorafenib is metabolized primarily in 
the liver and undergoes oxidative metabolism, mediated by cytochrome P450 3A4 (CYP3A4), as well as 
glucuronidation mediated by UGT1A9. Sorafenib conjugates may be cleaved in the gastrointestinal tract by 
bacterial glucuronidase activity, allowing reabsorption of unconjugated drug. Following oral administration 
of a 100 mg dose of a solution formulation of Sorafenib, 96% of the dose was recovered within 14 days, 
with 77% of the dose excreted in faeces, and 19% of the dose excreted in urine as glucuronidated 
metabolites. Unchanged Sorafenib, accounting for 51% of the dose, was found in faeces but not in urine, 
indicating that biliary excretion of unchanged drug might contribute to the elimination of Sorafenib. 
Sorafenib accounts for approximately 70–85% of the circulating analytes in plasma at steady state. Eight 
metabolites of Sorafenib have been identified, of which five have been detected in plasma. The main 
circulating metabolite of Sorafenib in plasma, the pyridine N-oxide, shows in vitro potency similar to that 
of Sorafenib. This metabolite comprises approximately 9-16% of circulating analytes at steady state. 
Neither age nor gender and race influence Sorafenib PK. 
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No relationship was observed between Sorafenib exposure and renal function in subjects with normal renal 
function, mild, moderate or severe renal impairment. 
The PK of Sorafenib in Child-Pugh A and B non-HCC patients were similar to the PK in healthy 
volunteers. There are no data for patients with Child-Pugh C (severe) hepatic impairment. Sorafenib is 
mainly eliminated via the liver, and exposure might be increased in this patient population. 
 
7.3 Drugs interactions 
Sorafenib is metabolized by CYP3A4 such as Sunitinib, Pazopanib and Vandetanib and it seems to be the 
more susceptible to CYP3A4 inducers or inhibitors [63].  
Sorafenib inhibited CYP2B6, CYP2C8 and CYP2C9 in vitro with similar potency. However, in clinical PK 
studies, concomitant administration of Sorafenib 400 mg twice daily with Cyclophosphamide, a CYP2B6 
substrate, or Paclitaxel, a CYP2C8 substrate, did not result in a clinically meaningful inhibition. These data 
suggest that Sorafenib at the recommended dose of 400 mg twice daily may not be an in vivo inhibitor of 
CYP2B6 or CYP2C8. 
Additionally, concomitant treatment with Sorafenib and Warfarin, a CYP2C9 substrate, did not result in 
changes in mean prothrombin time-international normalized ratio compared to placebo. Thus, also the risk 
for a clinically relevant in vivo inhibition of CYP2C9 by Sorafenib may be expected to be low. However, 
patients taking Warfarin or Phenprocoumon should have their international normalized ratio checked 
regularly. 
Concomitant administration of Sorafenib and Midazolam, Dextromethorphan or Omeprazole, which are 
substrates for cytochromes CYP3A4, CYP2D6 and CYP2C19 respectively, did not alter the exposure of 
these agents. This indicates that Sorafenib is neither an inhibitor nor an inducer of these cytochrome P450 
isoenzymes. Therefore, clinical PK interactions of Sorafenib with substrates of these enzymes are unlikely. 
As already described above, although Sorafenib is metabolized by CYP3A4, which can be inhibited or 
induced by various other drugs and environmental chemicals, biliary excretion of the unchanged parent 
drug accounts for more than half of the elimination of Sorafenib, and this route of elimination is not 
affected by agents that inhibit CYP3A4 activity. A study examining concomitant administration of 
Ketoconazole, a CYP3A4 inhibitor, with Sorafenib in healthy male volunteers demonstrated no change in 
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the PK of Sorafenib [64]. 
Potent CYP3A4 inducers may increase Sorafenib metabolism, but no clinical studies have evaluated this 
potential interaction [65].  
 
7.4 Protein p-glycoprotein (P-gp)-substrates 
In vitro, Sorafenib has been shown to inhibit the transport P-gp. Increased plasma concentrations of P-gp 
substrates such as digoxin cannot be excluded with concomitant treatment with Sorafenib. In vitro, 
Sorafenib inhibited glucuronidation via UGT1A1 and UGT1A9 [63,66].  
The clinical significance of this inhibition is not clear and drugs that are metabolized by these enzymes 
should be used with caution in patients treated with Sorafenib due to a potential risk of drug interactions. 
Sorafenib was demonstrated to have a moderate affinity for several members of the ATP-binding cassette 
sub-family (ABC).  
In LLC-PK1, Caco-2, K562, and MDCKII cells, it was shown that Sorafenib is a moderate substrate for the 
efflux transporter ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) [67].  
In vivo, Sorafenib was also demonstrated to be a substrate of ABCG2 and perhaps, ABCB1. Mice 
completely lacking both functional ABCB1 and ABCB2 and administered with oral Sorafenib had a higher 
accumulation of this drug in the brain than mice lacking either of the transporters alone.  
 
7.5 Combination with other anti-neoplastic agents  
In clinical studies Nexavar has been administered with a variety of other anti-neoplastic agents at their 
commonly used dosing regimens including Gemcitabine, Cisplatin, Oxaliplatin, Paclitaxel, Carboplatin, 
Capecitabine, Doxorubicin, Irinotecan, Docetaxel and Cyclophosphamide. Sorafenib had no clinically 
relevant effect on the PK of Gemcitabine, Cisplatin, Oxaliplatin or Cyclophosphamide. 
Sorafenib was given in phase I clinical trials in combination with Carboplatin, Dacarbazine, Gemcitabine, 
Oxaliplatin, and Paclitaxel, with no detectable drug interactions observed [65]. However, the Doxorubicin 
area under curve was 47% greater when coadministered with Sorafenib, although no significant difference 
in toxicity was observed despite the greater Doxorubicin exposure [68]. When coadministered with 
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Irinotecan, exposure was greater for both Irinotecan (26%–42%) and its active metabolite SN-38 (70%–
120%), but diarrhea from Irinotecan was not appreciably worse with the combination [69].  
 
7.6 Sorafenib and other targeted agents 
A phase I dose-escalation trial of Sorafenib and Bevacizumab was performed on 39 patients with various 
cancers at below-recommended single-agent doses [70]. This combination showed promising clinical 
activity in particular in ovarian cancer, but the rapidity and frequency of dose reductions indicated an 
intolerable long-term dosage and the need for alternative dosing schedules.  
Another phase I study reported that intermittent Sorafenib dosing with Bevacizumab had clinical activity, 
and fewer patients required a Sorafenib dose reduction and fewer side effects were observed [71]. 
The combination of Sorafenib with Erlotinib was investigated in a phase I trial: it was well-tolerated and 
showed promising activity [72]. In a phase II trial for the combination, a higher progression-free survival 
(PFS) and OS was seen in the epidermal growth factor receptor (EGFR) wild-type and the EGFR FISH-
negative patients with advanced non-small cell lung cancer, compared to Erlotinib alone [73]. However, 
additional studies are needed to confirm the benefit of this combination. Recently, a pre-clinical study of 
the combination of Sorafenib with Erlotinib or Cetuximab showed synergistic antitumor activity in both 
colorectal cancer and non-small cell lung cancer [74].  
A phase I study investigated Sorafenib plus interferon (IFN)-α-2a in advanced RCC and melanoma and it 
showed preliminary antitumor activity and the doses were well-tolerated [75]. Another study was conducted 
on the combination of Sorafenib and IFN-α-2b in advanced RCC patients and it showed substantial activity, 
but the toxicity exceeded that of either drug alone [76]. However, dose reductions and breaks between 
cycles allowed for long term therapy. In contrast, a more recent phase II study that investigated the 
combination of Sorafenib and pegylated IFN-α-2b in metastatic melanoma patients showed modest clinical 
activity and serious side effects, such as fatal bleeding complications [77]. This effect could have been 
linked to a different dosing schedule or the use of Peg-IFN-α-2b instead of conventional IFN-α.  
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7.7 Undesirable effects 
The most common adverse reactions were diarrhoea, rash, alopecia and hand-foot syndrome, while the most 
important serious adverse reactions were myocardial infarction/ischaemia, gastrointestinal perforation, drug 
induced hepatitis, haemorrhage, and hypertension/hypertensive crisis. 
Adverse reaction's frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), 
uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), not known (cannot be estimated from the 
data available). 
Undesirable effects are presented in the Table 3 [78].  
 
8. Clinical studies in thyroid cancer 
After previous studies showing that Sorafenib was able to inhibit oncogenic RET mutants, V600EBRAF, and 
angiogenesis and growth of orthotopic anaplastic thyroid cancer (ATC) xenografts in nude mice, some 
clinical trials proved the effectiveness of Sorafenib in advanced thyroid cancer [49,79]. 
There have been different phase II trials of Sorafenib [BAY 43-9006, 400 mg bis in die (b.i.d.)]. The first 
trial of Sorafenib (400 mg b.i.d.) was conducted on 30 DTC patients, and PR was reported in 7 patients and 
SD in 16 patients [28]. 
The second trial reported a PR in 6 patients and SD for 6 months or more in 23 of the 41 patients with PTC, 
but therapy was ineffective in the 11 patients with FTC or poorly DTC and in the 4 patients with ATC [29]. 
In the third trial, which was conducted on 32 DTC patients, a PR was reported in 8 patients and SD in 11 
patients [30]. Greater efficacy of Sorafenib was seen in PTC in particular in the ones with a BRAF 
mutation, than in poorly DTC, and it had no effect on iodine uptake. A phase III trial comparing PFS is 
under way in which Sorafenib and placebo are being administered to patients with radioiodine resistant 
metastatic DTC. 
A further phase II trial of Sorafenib in patients with advanced MTC (16 sporadic, or 25 hereditary) has been 
conducted. Among 16 patients with sporadic MTC, one achieved PR (6.3%), 14 had SD (87.5%), and one 
was not-evaluable. Median PFS (mPFS) was 17.9 months. The treatment in MTC hereditary patients was 
prematurely terminated because of slow accrual [37]. 
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Ahmed et al. [32] evaluated Sorafenib in a UK population with progressive locally advanced/metastatic 
MTC or DTC with non-radioiodine-avid disease. Thirty-four patients were recruited (15 medullary and 19 
differentiated) and were treated with Sorafenib 400 mg twice daily. After 6 months, the radiological 
response rate (RR) was 15% and a further 74% of patients achieved SD in the first 6 months. After 12 
months of treatment, the radiological RR was 21%. In the MTC patients, the radiological RR at 12 months 
was 25% and OS was 100%. In DTC patients corresponding rates were 18 and 79% respectively. Median 
overall and PFS points were not reached at 19 months. The most common adverse events included hand-
foot syndrome, other skin toxicities, diarrhoea and alopecia. Dose reduction was required in 79% patients. 
Median time on treatment was 16.5 months. The majority of the patients showed radiological and 
biochemical stabilization of disease despite dose reductions [32].  
Capdevila et al. [31] tested Sorafenib in patients with advanced thyroid cancer among 30 evaluable patients 
and they observed PRs in 9 and SD in 13 patients. With a median follow-up of 11 months, the mPFS was 
11.6 months. Interestingly, six out of 12 (50%) patients with MTC obtained a PR, indicating that the drug 
might be effective in MTC, although the small number of patients requires further prospective studies. 
Due to these results, Koh et al. [50] tried to identify potential combinatorial strategies to improve the 
efficacy of Sorafenib in patients with progressive MTC. Two human MTC cell lines, TT and MZ-CRC-1, 
which harbor endogenous C634W and M918T RET mutations respectively, were tested with Sorafenib, 
Everolimus and AZD6244 (Mek inhibitor) alone and in combination. The results showed that Sorafenib 
was the most active compound and had a synergistic effect with AZD6244 (p<0.001 for each cell line) [50].  
Recently, Capdevila et al. [33] designed a retrospective analysis of patients with metastatic thyroid cancer 
treated with Sorafenib in seven Spanish referral centers. Thirthy-four patients were included between June 
2006 and January 2010. They were all not suitable for any traditional therapies and received 400 mg twice a 
day. The primary end point was objective RR, secondary was toxicity, mPFS, mOS and correlation between 
tumor marker levels (Tg, calcitonin and carcinoembryogenic antigen). Sixteen patients presented DTC (7 
papillary, 9 follicular), 15 MTC, and 3 ATC. Eleven patients (32%) achieved PR and 14 (41%) had SD 
beyond 6 months. RRs were 47% (7 of 15) for MTC, 19% (3 of 16) for DTC and 33% (1of 3) for ATC. 
With a median follow up of 11.5 months, mPFS were 13.5, 10.5 and 4.4 months for DTC, MTC and ATC 
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respectively. A significant decrease in tumor markers was also reported. In this trial, Sorafenib showed 
antitumor efficacy in all histological subtypes of thyroid cancer [33].  
Thanks to the phase II trial results, it has been initiated a multicenter, double-blind randomized phase III 
study evaluating the efficacy and safety of Sorafenib compared to placebo in locally advanced/metastatic 
radioactive iodine (RAI)-refractory DTC that is still ongoing [80]. 
 
9. The DECISION trial  
The DECISION trial was designed to assess the ability of Sorafenib to improve PFS in patients with locally 
advanced or metastatic, RAI-refractory DTC. The duration of the trial is expected to be 30 months. The 
primary endpoint is PFS; secondary includes OS, time to disease progression, disease control rate, RR, 
duration of response, safety and PK analysis. The efficacy and safety are evaluated respectively every 56 
days (two cycles) and 28 days (1 cycle) for the first 8 months and every 56 days after.  
About 380 patients, enrolled in 19 countries (USA, Italy, Germany, France, Poland, UK, Denmark, Spain, 
Sweden, Netherlands, Austria, Belgium, China, South Korea, Japan, Russia, Slovakia, Bulgaria and Saudi 
Arabia) and stratified according to age (<60 vs >60 years) and geographic region (North America vs Europe 
vs Asia) will be randomized 1:1 to receive placebo or Sorafenib. The inclusion criteria are: age >18, lie 
expectancy of at least 12 weeks, locally advanced or metastatic DTC (papillary, follicular, Hurtle cell or 
poorly differentiated cancer) with at least one measurable lesion as measured by computer tomography or 
magnetic resonance imaging and disease progression within 14 months. All patients must have RAI-
refractory disease, defined as a target lesion with no iodine uptake on a post RAI scan performed under 
conditions of a low iodine diet and adequate TSH elevation or recombinant human TSH stimulation. Some 
patients who have had some iodine uptake may be also eligible.  
Addictional inclusion criteria are a performance status < 2 according to Eastern Cooperative Oncology 
Group, adequate TSH suppression (<0.5 mU/L) absence of renal ad liver failure and adequate bone marrow 
function. Patients who have yet received any treatment with TKI, monoclonal antibodies against VEGFRs 
or other targeted agents, cytotoxic chemotherapy or Thalidomide were excluded.  
Patients are being randomized to receive Sorafenib 400 mg or matching placebo, twice daily in a double-
blind fashion. The treatment will be continued until radiographically documented disease progression, 
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unacceptable toxicity or the study endpoint. In the case of confirmed disease progression, patients who 
receive placebo were crossed-over to Sorafenib.  
Dose modifications or interruptions are feasible according to specific criteria: grade 2-3 hand-foot skin 
reaction and other adverse events [81].  
A recent press release has communicated that DECISION trial has met its primary endpoint increasing 
mPFS.  
 
10. Latest results  
Schneider et al. [34] recently published a long term analysis on the efficacy of Sorafenib (400 mg twice a 
daily) in 31 patients with progressive metastatic or locally advanced RAI-refractory DTC. Encouraging 
results have been reported: mPFS was 18 months (95% confidence interval: 7–29 months) and mOS was 
34.5 months (95% confidence interval: 19–50 months). Eight patients (31%) achieved a PR and 11 patients 
(42%) showed SD after a median follow-up of 25 months (range 3.5–39 months). Toxicity mostly included 
hand foot syndrome, weight loss, diarrhoea and rash [34]. 
Furthermore, the therapeutic effect of Sorafenib has been recently shown in a patient with brain metastasis 
from FTC [82]. 
In another study, 17 patients with progressive DTC refractory to RAI were treated with Sorafenib used off-
label independently from their performance status. Median follow-up was 15.5 months. Clinical benefit was 
obtained in 71% of subjects (30% PR and 41% SD). Sorafenib was mostly well tolerated but a high 
incidence of fatal events was reported (3 patients died from severe bleeding events and 2 from cardiac 
arrest). The best responses were observed in lymph nodes and lung. Baseline Tg levels and the Tg response 
to treatment were correlated to both radiological response and PFS. Baseline fluorodeoxyglucose positron 
emission tomography assessment and early fluorodeoxyglucose positron emission tomography response 
were correlated to radiological response [35].  
Savvides et al. [36] treated twenty patients with ATC with Sorafenib 400 mg twice daily. Two of 20 
patients had a PR (10%) and an additional 5 of 20 (25%) had SD. The duration of response in the two 
responders was 10 and 27 months respectively. For the patients with SD the median duration was 4 months 
(range 3–11 months). The overall mPFS was 1.9 months with a median and 1-year survival of 3.9 months 
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and 20% respectively. Toxicity was manageable as previously described for Sorafenib including 
hypertension and skin rash [36]. 
Cohen et al. evaluated the combination therapy (Withaferin+Sorafenib) against anaplatic (SW1736) and 
papillary (BCPAP) carcinoma cell lines. Combination therapy with Sorafenib+Withaferin showed 
synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis. This 
combination achieved potent anticancer activity with lower overall doses of Sorafenib, indicating a 
potential strategy to decrease Sorafenib toxicity in future translational studies [83].  
Iyer et al. described the case of an 8-year old boy with respiratory failure secondary to diffuse micronodular 
PTC requiring mechanical ventilation and subsequent delay in definitive therapy. The boy was treated with 
Sorafenib and subsequently with radioiodine-131, with a good response to the therapy. The Authors  
suggested that Sorafenib could be considered for gap therapy while the patient recovers pulmonary function 
[84].  
In Sorafenib-treated patients with metastic cancer, disease stabilization and tumor shrinkage wer short-lived 
and drug resistance occured. A study explored the Sorafenib treatment escape mechanisms to overcome 
their drawbacks, showing that mammalian target of Rapamycin (mTOR) complex 2 activation is an escape 
mechanism from Sorafenib treatment. When Sorafenib is combinend with Everolimus, its antitumor 
activity is increased by complete inhibition of mTOR pathway [85]. 
It has been recently shown, the AKT/mTOR pathway is particularly overactivated in human cPTC 
harboring the V600EBRAF mutation. These results suggest that the mTOR pathway could be a good target 
to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the 
V600EBRAF mutation [86].  
We include the current clinical researches with Sorafenib in different types of thyroid cancer (Table 4; 
[87]).  
 
11. Targeted Therapies Limits 
Tumor cells often devise strategies to bypass the effects of anti-neoplastic agents and selection of therapy-
resistant clones is frequently the reason for treatment failure. However, the possibility of testing the 
sensitivity of primary DePTC cells from each subject to different TKIs could increase the effectiveness of 
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the treatment. In fact, in vitro chemosensitivity tests are able to predict in vivo effectiveness in 60% of 
cases [88]; while, it is well known that a negative chemosensitivity test in vitro is associated with a 90% of 
ineffectiveness of the treatment in vivo, allowing the administration of inactive chemotherapeutics to these 
patients to be avoided [88].  
It has been recently demonstrated that it is possible to test the anti-neoplastic activity of different 
compounds in primary ATC cells obtained from each patient [51, 89-91]. Interestingly, more recently, two 
new multi-targeted kinase inhibitors (CLM3 and CLM29 inhibit several targets, including RET, EGFR, and 
VEGFR and have an antiangiogenic effect) have been shown to have an anti-tumoral effect not on the 
normally used cell lines, that are quite different from the tumor of the patients themselves, but directly on 
primary DePTC of patients refractory to the radioiodine therapy [48], or in ATC opening the way to the 
possibility of personalizing the kinase inhibitors therapy in each patient. 
 
12. Conclusions 
Sorafenib is an oral multikinase inhibitor with antiproliferative, antiangiogenic and proapoptotic effects that 
seems to be a promising therapeutic option in patients with advanced thyroid cancer not responsive to 
tradionally therapeutic strategies. 
Nowadays, several studies are ongoing to evaluate long term efficacy and tolerability of Sorafenib, 
especially on thyroid tumors. 
Further research is needed to determine the ideal targeted therapy based on the molecular characterization 
of the tumor and of the host factors to obtain the best response in terms of survival and quality of life [92]. 
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Table 1. Clinical trials with targeted therapies against RET in patients with thyroid cancer. 
 
Drug 
 
 
Pathway inhibited 
 
 
Thyroid cancer 
 
 
Responses 
 
 
Author, reference 
n° 
   
Follicular derived 
Thyroid Cancer 
  
Sorafenib 
 
RAF, RET, VEGFR 
 
30 DTC 
 
7(23%)PR;  
16(53%)SD  
(DTC) 
Gupta-Abramson 
V et al. [28] 
 
Sorafenib 
 
RAF, RET, VEGFR 
 
41 PTC 
11 FTC 
4 ATC 
 
6(15%)PR;  
23(56%)SD (PTC) 
No response (FTC) 
No response (ATC) 
Kloos RT et al. 
[29] 
 
Sorafenib RAF, RET, VEGFR 
 
32 DTC 
 
8(25%)PR;  
11(34%)SD (DTC) 
Hoftijzer H et al. 
[30] 
 
 
Sorafenib RAF, RET, VEGFR 30 advanced 
thyroid cancer 
9(30%)PR; 
13(36%)SD 
Capdevila J et al. 
[31] 
Sorafenib RAF, RET, VEGFR 19 DTC Twelve months  
radiological RR: 
DTC 18% 
Ahmed M et al. 
[32] 
 
Sorafenib RAF, RET, VEGFR 7 PTC, 9 FTC, 3 
ATC) 
7 PTC, 9 FTC : RR 
19%, 
3 ATC : RR 33% 
Capdevila J et al. 
[33] 
 
 
  
30 
Sorafenib RAF, RET, VEGFR 31 advanced 
thyroid cancer  
PR 8 (31%) 
SD 11 (42%) 
Schneider TC et 
al. [34] 
 
Sorafenib RAF, RET, VEGFR 17 progressive 
DTC      
PR 30%, 
 SD 41%  
Marotta V et al. 
[35] 
 
Sorafenib RAF, RET, VEGFR 20 ATC                            2 PR (10%) 
duration of 
response 
respectively 10 and 
27 months, 5 SD 
(25%) median 
duration 4 months 
(range 3-11 
months) 
Savvides P et al. 
[36] 
 
  Medullary 
Thyroid Cancer 
  
Sorafenib RAF, RET, VEGFR 
 
16 sporadic MTC 1(6%)PR; 
14(88%)SD 
Lam ET et al. 
[37] 
Imatinib 
 
VEGFR-2, RET 
 
15 MTC 
 
4(27%)SD (MTC) de Groot JW et 
al. [38] 
Vandetanib VEGFR-2, EGFR, RET 
 
30 MTC hereditary 
 
6(20%)PR, 
16(53%)SD (MTC) 
Wells SA Jr et al. 
[39] 
Vandetanib 
 
VEGFR-2, EGFR, RET 
 
19 MTC hereditary 
 
3(16%)PR, 
10(53%)SD (MTC) 
Robinson BG et 
al. [40] 
 
Sorafenib RAF, RET, VEGFR 15 MTC Twelve months  
radiological RR: 
Ahmed M et al. 
[32] 
  
 
31 
MTC 25%;   
Sorafenib RAF, RET, VEGFR 15 MTC 15 MTC : PR 
11(32%), SD 14 
(41%), RR 47% 
 
Capdevila J et al. 
[33] 
 
     
VEGFR = vascular endothelial growth factor receptor; EGFR = epidermal growth factor receptor; DTC = 
differentiated thyroid cancer; ATC = anaplastic thyroid cancer; PTC = papillary thyroid cancer; FTC = 
follicular thyroid cancer; MTC = medullary thyroid cancer; PR = partial response; SD = stable disease; CR 
= complete response; RR= rate response. 
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Table 2. In vitro studies with targeted therapies against RET in papillary, medullary and anaplastic thyroid 
cancer. 
 
Drugs Cell type  Results Xenografts 
(yes/no) 
Anti-neoplastic 
effect in 
xenografts 
(yes/no) 
Author, 
reference n° 
ZD6474 PTC cell line,  Prol+ Yes Yes Carlomagno F et 
al. [41] 
RPI-1 MTC cell line Prol+ Yes Yes Cuccuru G et al. 
[42] 
CEP-701, CEP-
751, CEP-2563 
MTC cell line Prol+ Yes Yes Strock CJ et al. 
[43] 
PP2 PTC cell line Prol+ No - Carlomagno F et 
al. [44] 
Vandetanib, 
XL184 
 
MTC cell line Prol+ No - Verbeek HH et 
al. [45] 
XL184 PTC cell line  No - Verbeek HH et 
al. [45] 
Motesanib MTC cell line  Yes Yes Coxon A et al. 
[46] 
Withaferin A MTC cell line Prol+, apo+ Yes Yes Samady AK et 
al. [47] 
CLM3, CLM29 DePTC cell 
line 
Prol+, apo+ Yes Yes Antonelli A et al. 
[48] 
Sorafenib ATC cell  Prol +, apo +    Yes Yes Kim S et al. [49]             
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lines      
Sorafenib 
Everolimus, 
AZD 6244   
MTC cell 
lines (TT, 
MZ-CRC-1) 
   Koh YW et al. 
[50]         
                                                                     
CLM94 ATC cells, 
ATC cell line 
(AF) in CD 
nu/nu mice; 
HMVEC-d, 
8305  C cells 
Prol +, apo + Yes Yes Antonelli A et al. 
[51] 
PTC = papillary thyroid cancer; DePTC = dedifferentiated papillary thyroid cancer; MTC = medullary 
thyroid cancer; ATC = anaplastic thyroid cancer. 
Inhibition of proliferation (prol+), induction of apoptosis (apo+). 
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Table 3. Adverse reactions from several clinical study of patients treated with Sorafenib, and from post 
marketing report (from EMA).  
 
 
Classification (systems 
or organ) 
Very common ≥ 
1/10 
Common 
≥ 1/100, <1/10 
Uncommon 
≥1/1000, <1/100 
Rare 
Infections   Infection 
Folliculitis 
 
Hemolymphopoietic 
Diseases 
Lymphopenia Leukopenia 
Neutropenia 
Thrombocytopenia 
  
Immune system 
disorders 
  Hypersensivity (skin 
reaction and nettle rash) 
Angioedema, 
anaphylaxis shock 
Endocrine disorders   Hypo/hyperthyroidism  
Metabolic and 
nutritional disorders 
Hypophosphatemia Anorexia 
Hypocalcemia 
Hyponatriemia 
Dehydration 
 
Psychiatric disorder  Depression   
Neurological Diseases  Periferical sensorial 
neurophaty 
Reversible white matter 
encephalopathy 
 
Ear disease  Tinnitus   
Cardiac diseases  Congestive hearth 
failure, myocardial 
ischaemia 
 QT prolungation 
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Vascular diseases Hypertension, 
bleeding (from the 
gastrointestinal 
tract, respiratory 
tract; cerebral 
haemorrhage) 
 Hypertensive crisis  
Respiratory tract end 
mediastinic diseases 
 Raucousness Rhinorrhea, interstitial 
pneumonial like diseases 
 
Gastrointestinal  tract 
diseases 
Diarrhea, nausea, 
vomit 
Constipation, 
stomatitis, 
dyspepsia, 
dysphagia 
Gastro-oesophageal reflux, 
gastritis, pancreatitis, 
bowel perforation 
 
Hepatobiliary diseases   Jaundice, cholecystitis Drug related 
hepatitis 
Skin  Rash, alopecia, 
hand-foot 
syndrome, itch 
Skin dryness, 
exfoliative 
dermatitis, acne  
Erythema multiforme, 
eczema 
Stevens Johnsons 
syndrome, 
vasculitis 
Muscle skeletal system 
and connettive tissue 
disease 
 Arthralgia, myalgia  Rhabdomyolysis 
Renal diseases  Renal failure   
 Diseases of 
reproductive system 
and breast 
 Erectile dysfunction Gynecomastia  
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Diseases related to the 
way of administration 
Fatigue, pain 
(mouth, abdomen, 
bone, oncologic), 
headache 
Asthenia, fever,  
influenza like 
syndrome 
  
Laboratory exams Increasing levels of 
amylase and lipase 
Weight loss, 
increasing levels of 
hepatic enzyme 
Alteration of INR value   
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Table 4. Current clinical research with Sorafenib in different types of thyroid cancer (from 
www.clinicaltrials.gov ). 
 
 
 
Status/Phase Study Condition Intervention  
Active, not 
recruiting/Phase II 
Combination of 
Temsirolimus and 
Sorafenib in the 
Treatment of 
Radioactive Iodine 
Refractory Thyroid 
Cancer 
 
Thyroid Cancer Drug: Temsirolimus 
and Sorafenib 
Unknown/Phase II Phase II Trial of 
Sorafenib (Nexavar) 
in Patients With 
Advanced Thyroid 
Cancer 
 
Metastatic 
Differentiated 
Thyroid Cancer;   
Metastatic 
Poorly 
Differentiated 
Thyroid Cancer;   
Metastatic 
Anaplastic 
Thyroid Cancer;   
Metastatic 
Medullary 
Thyroid Cancer 
 
Drug: Sorafenib 
Unknown/Phase II Study of Everolimus 
and Sorafenib in 
Patients With 
Advanced Thyroid 
Cancer Who 
Progressed on 
Sorafenib Alone 
Differentiated 
Thyroid Cancer 
Drug: Everolimus;   
Drug: Sorafenib  
Active, not 
recruiting/Phase II 
Sorafenib Tosylate 
in Treating Patients 
With Metastatic, 
Locally Advanced, 
or Recurrent 
Medullary Thyroid 
Cancer 
 
Multiple 
Endocrine 
Neoplasia;   
Recurrent 
Thyroid Cancer;   
Thyroid Gland 
Medullary 
Carcinoma 
 
Drug: Sorafenib 
tosylate;    
Genetic: molecular 
genetic technique and 
mutation analysis;   
immunohistochemistry 
staining method; 
diagnostic laboratory 
biomarker analysis;   
pharmacological study 
 
Active, not 
recruiting/Phase II 
Evaluating the 
Combination of 
Everolimus and 
Sorafenib in the 
Treatment of 
Thyroid Cancer 
 
Thyroid Cancer Drug: Sorafenib with 
Everolimus 
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Terminated 
Has Results/Phase 
II 
Sorafenib in Treating 
Patients With 
Advanced Anaplastic 
Thyroid Cancer 
 
Anaplastic 
Thyroid Cancer;   
Recurrent 
Thyroid Cancer 
 
Drug: Sorafenib 
tosylate 
 
Completed /Phase 
II  
Sorafenib Tosylate 
in Treating Patients 
With Locally 
Advanced, 
Metastatic, or 
Locally Recurrent 
Thyroid Cancer 
Anaplastic 
Thyroid Cancer;   
Insular Thyroid 
Cancer;   
Recurrent 
Thyroid Cancer;   
Stage III 
Follicular 
Thyroid Cancer;   
Stage III 
Papillary 
Thyroid Cancer;   
Stage IV 
Follicular 
Thyroid Cancer;   
Stage IV 
Papillary 
Thyroid Cancer 
 
Drug: Sorafenib 
tosylate;    
Other: laboratory 
biomarker analysis; 
pharmacological 
study;   
Radiation: 
fludeoxyglucose F 18;   
Procedure: positron 
emission tomography;   
Procedure: dynamic 
contrast-enhanced 
magnetic resonance 
imaging 
 
Completed/Phase 
II 
Sorafenib as 
Adjuvant to 
Radioiodine Therapy 
in Non-Medullary 
Thyroid Carcinoma 
 
Thyroid Cancer Drug: Sorafenib 
(Nexavar) 
Withdrawn/Phase 
II 
Efficacy and Safety 
Study of Sorafenib to 
Treat Advanced 
Medullary Thyroid 
Carcinoma 
 
Medullary 
Thyroid 
Carcinoma 
Drug: Sorafenib 
Active, not 
recruiting/Phase III 
Nexavar® Versus 
Placebo in Locally 
Advanced/Metastatic 
RAI-Refractory 
Differentiated 
Thyroid Cancer 
 
Thyroid 
Neoplasms 
Drug: Sorafenib 
(Nexavar, BAY43-
9006);   Drug: Placebo 
 
Recruiting/Phase II RAD001 for Patients 
With Radioiodine 
Refractory Thyroid 
Cancer 
Thyroid Cancer Drug: RAD001 
 
 
 
